<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01917383</url>
  </required_header>
  <id_info>
    <org_study_id>IPC-01-2013</org_study_id>
    <nct_id>NCT01917383</nct_id>
  </id_info>
  <brief_title>A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma</brief_title>
  <official_title>A Phase II Multi-center, Randomized Study to Evaluate the Monocular Addition of Trabodenoson (INO-8875) Ophthalmic Formulation to Latanoprost Ophthalmic Solution Therapy in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inotek Pharmaceuticals Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Inotek Pharmaceuticals Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the intraocular pressure (IOP) lowering efficacy and
      the safety and tolerability profile of trabodenoson ophthalmic formulation compared to
      timolol maleate ophthalmic solution 0.5% in adults with ocular hypertension (OHT) or primary
      open-angle glaucoma (POAG) who are already receiving treatment with latanoprost ophthalmic
      solution 0.005% once every evening (QPM).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Criteria

      Inclusion Criteria:

        1. Subject has signed and dated the current informed consent form (ICF).

        2. Subject has the diagnosis of ocular hypertension (OHT) or primary open-angle glaucoma
           (POAG) (excluding secondary, pseudo-exfoliation, and pigment dispersion glaucomas).

        3. Aged 18 or older.

        4. Mean intraocular pressure (IOP) of ≥24 and ≤34 mm Hg.

      Exclusion Criteria:

        1. No significant visual field loss or any new field loss within the past year.

        2. Cup-to-disc ratio ≥0.8

        3. Central corneal thickness &lt;500 µm or &gt;600 µm

        4. A recent (acute) or chronic medical condition that might obfuscate the Subject's study
           data
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular Pressure (IOP)</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Primary Open-Angle Glaucoma (POAG)</condition>
  <condition>Ocular Hypertension (OHT)</condition>
  <arm_group>
    <arm_group_label>Trabodenoson Plus Latanoprost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental ophthalmic eye drop plus a prostaglandin analogue eye drop</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Timolol Plus Latanoprost</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A Beta-blocker eye drop plus a prostaglandin analogue eye drop</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trabodenoson</intervention_name>
    <description>Ophthalmic eye drop</description>
    <arm_group_label>Trabodenoson Plus Latanoprost</arm_group_label>
    <other_name>INO-8875</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Latanoprost</intervention_name>
    <description>Ophthalmic eye drop</description>
    <arm_group_label>Trabodenoson Plus Latanoprost</arm_group_label>
    <arm_group_label>Timolol Plus Latanoprost</arm_group_label>
    <other_name>Xalatan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Timolol</intervention_name>
    <description>Ophthalmic eye drop</description>
    <arm_group_label>Timolol Plus Latanoprost</arm_group_label>
    <other_name>Timoptic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject has signed and dated the current informed consent form (ICF).

          2. Subject has the diagnosis of ocular hypertension (OHT) or primary open-angle glaucoma
             (POAG) (excluding secondary, pseudo-exfoliation, and pigment dispersion glaucomas).

          3. Aged 18 or older.

          4. Mean intraocular pressure (IOP) of ≥24 and ≤34 mm Hg.

        Exclusion Criteria:

          1. No significant visual field loss or any new field loss within the past year.

          2. Cup-to-disc ratio ≥0.8

          3. Central corneal thickness &lt;500 µm or &gt;600 µm

          4. A recent (acute) or chronic medical condition that might obfuscate the Subject's study
             data
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chiltern</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2013</study_first_submitted>
  <study_first_submitted_qc>August 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2013</study_first_posted>
  <disposition_first_submitted>March 23, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>April 11, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 4, 2015</disposition_first_posted>
  <last_update_submitted>November 28, 2017</last_update_submitted>
  <last_update_submitted_qc>November 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glaucoma</keyword>
  <keyword>primary open angle glaucoma</keyword>
  <keyword>ocular hypertension</keyword>
  <keyword>adenosine agonist</keyword>
  <keyword>eye drop</keyword>
  <keyword>trabodenoson</keyword>
  <keyword>trabecular meshwork</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tetrahydrozoline</mesh_term>
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

